A Tazi

Publications (55)269.77 Total impact

• Article: Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis.

  A Bergeron, C Godet, S Chevret, G Lorillon, R Peffault de Latour, T de Revel, M Robin, P Ribaud, G Socié, A Tazi
  [show abstract] [hide abstract]
  ABSTRACT: Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic SCT (HSCT) is recognized as a new-onset obstructive lung defect (OLD) in pulmonary function testing and is related to pulmonary chronic GVHD. Little is known about the different phenotypes of patients with BOS and their outcomes. We reviewed the data of all allogeneic HSCT recipients referred to our pulmonary department for a non-infectious bronchial disease between 1999 and 2010. We identified 103 patients (BOS (n=77), asthma (n=11) and chronic bronchitis (n=15)). In patients with BOS, we identified two functional phenotypes: a typical OLD, that is, forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio <0.7 (n=53), and an atypical OLD with a concomitant decrease in the FEV1 <80% and FVC <80% predicted with a normal total lung capacity (n=24). The typical OLD was characterized by more severe FEV1 and fewer centrilobular nodules on the computed tomography scan. The FEV1 was not significantly affected during the follow-up, regardless of the phenotype. In addition to acute and extensive chronic GVHD, only the occurrence of BOS soon after transplantation and the intentional treatment of BOS with steroids were associated with a poor survival. The determination of patient subgroups should be explored to improve the management of this condition.Bone Marrow Transplantation advance online publication, 3 December 2012; doi:10.1038/bmt.2012.241.
  Bone marrow transplantation 12/2012; · 3.00 Impact Factor
• Article: Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study.

  B Crestani, J Chapron, B Wallaert, E Bergot, P Delaval, D Israel-Biet, J Lacronique, I Monnet, M Reynaud-Gaubert, A Tazi, R Lebtahi, M-P Debray, M Brauner, M Dehoux, Q Dornic, M Aubier, F Mentré, X Duval
  European Respiratory Journal 03/2012; 39(3):772-5. · 5.89 Impact Factor
• Article: Rituximab in bronchiolitis obliterans after haematopoietic stem cell transplantation.

  G Lorillon, M Robin, V Meignin, P Ribaud, B Lescoeur, D Gossot, G Socié, A Tazi, A Bergeron
  European Respiratory Journal 08/2011; 38(2):470-2. · 5.89 Impact Factor
• Article: [Acute interstitial pneumonia: diagnostic approach and management].

  S Feuillet, A Tazi
  [show abstract] [hide abstract]
  ABSTRACT: Acute interstitial pneumonia (AIP) encompasses a spectrum of pulmonary disorders characterized by involvement of the lung interstitium and distal airways (bronchioles and alveoli). The onset of respiratory symptoms is acute, most often within two weeks. Most AIP take place de novo, but sometimes represent an acute exacerbation of chronic lung disease. The clinical presentation of AIP comprises rapidly progressive dyspnoea, associated sometimes with cough, fever, myalgia and asthenia. Chest radiography shows diffuse pulmonary opacities. The associated hypoxemia may be severe enough to cause acute respiratory failure. Underlying aetiologies are numerous and variable, particularly in relation to the underlying immune status of the host. Various histopathological entities may be responsible for AIP although diffuse alveolar damage is the predominant pattern. The diagnostic approach to a patient presenting with AIP is to try to determine the most likely underlying histopathological pattern and to search for a precise aetiology. It relies mainly on a meticulous clinical evaluation and accurate biological investigation, essentially guided by the results of bronchoalveolar lavage performed in an area identified by abnormalities on high resolution computed tomography of the lungs. Initial therapeutic management includes symptomatic measures, broad-spectrum antibiotic treatment adapted to the clinical context, frequently combined with systemic corticosteroid therapy.
  Revue des Maladies Respiratoires 06/2011; 28(6):809-22. · 0.59 Impact Factor
• Article: Pulmonary Langerhans cell histiocytosis associated with Hodgkin's lymphoma.

  S Feuillet, L Louis, A Bergeron, A Berezne, M-L Dubreuil, M Polivka, E Oksenhendler, A Tazi
  European Respiratory Review 03/2010; 19(115):86-8.
• Article: [Prospective evaluation of the efficacy of the combination of budesonide/formoterol in obstructive airway disease after allogeneic hematopoietic stem cell transplantation].

  A Bergeron, K Chagnon, S Feuillet, S Chevret, A Tazi
  [show abstract] [hide abstract]
  ABSTRACT: Although it has not been evaluated prospectively, the usual treatment for obstructive airway disease after allogeneic hematopoietic stem cell transplantation, which is related to graft versus host disease, consists of intensification of systemic immunosuppressive therapy. However, this treatment has a limited efficacy and is associated with a significant number of serious adverse effects, particularly infectious. Alternative treatments are therefore required. Recently, clinical and functional improvement in patients with obstructive airway disease following allogenic hematopoietic stem cell transplantation treated with inhaled combined Budesonide/Formoterol has been retrospectively reported. The present prospective multi-centered, randomised double-blind trial is designed to evaluate the efficacy of the combination of budesonide/formoterol (400/12 microg 2 inhalations bid) versus placebo in patients with moderate to severe obstructive airway disease, not requiring initiation or intensification of systemic immunosuppressive therapy for extra thoracic graft versus host disease. The primary outcome will be the improvement of FEV1 at 1 month of treatment. The secondary outcomes will be the clinical and functional pulmonary improvements at 6 months. The leading hypothesis is that patients treated with inhaled combined Budesonide/Formoterol will show significant improvement of their clinical symptoms and pulmonary functional testing.
  Revue des Maladies Respiratoires 09/2009; 26(7):794-800. · 0.59 Impact Factor
• Article: [Late onset, non-infectious pulmonary complications after haematological stem cell transplantation].

  A Bergeron, S Feuillet, V Meignin, G Socie, A Tazi
  [show abstract] [hide abstract]
  ABSTRACT: Non infectious pulmonary complications which frequently occur in the late follow-up of haemopoietic stem cell transplant (HSCT) recipients account for an increase in mortality and morbidity. Different histological entities have been described among which bronchiolitis obliterans is the most common. Because of the absence of prospective epidemiological studies and the difficulties in obtaining surgical lung biopsies from these frail patients little is known about these conditions. Although their pathogenesis is poorly understood they probably result from a chronic pulmonary graft versus host disease (GVHD). The introduction of or increase in systemic immunosuppressive treatment, usually indicated for controlling extra-thoracic manifestations of GVHD, may lead to the resolution of an organising pneumonia but is usually ineffective in the treatment of bronchiolitis obliterans. Current prospective cohort studies together with randomised prospective studies evaluating more targeted treatments should help determine the frequency, the risk factors and the precise characteristics of the different entities of late non-infectious pulmonary diseases following HSCT and should also improve their management. Furthermore, the recent demonstration of lung abnormalities in animal models of chronic GVHD, similar to those observed in humans, should allow a better understanding of the pathogenesis. The prevalence of these diseases is increasing throughout the world. More precise analysis, the identification of risk factors and study of the pathophysiological mechanisms involved should allow better understanding and management than at present.
  Revue des Maladies Respiratoires 03/2008; 25(2):173-83. · 0.59 Impact Factor
• Article: Combined inhaled steroids and bronchodilatators in obstructive airway disease after allogeneic stem cell transplantation.

  A Bergeron, A Belle, S Chevret, P Ribaud, A Devergie, H Esperou, L Ades, E Gluckman, G Socié, A Tazi
  [show abstract] [hide abstract]
  ABSTRACT: Bronchiolitis obliterans (BO) is a potentially life-threatening complication following allogeneic stem cell transplantation (SCT) and usually carries a poor prognosis. Immunosuppressive medications are the main treatment, but are rarely effective, especially when the disease is severe. Thus, both early detection and alternative therapeutic approaches of post SCT BO are needed. We report our experience with Budesonide/Formoterol, an inhaled steroid and long-acting bronchodilatator combination, in a group of patients with mild to moderately severe BO after SCT whose systemic immunosuppressive treatment had not been modified. Thirteen patients were treated. The diagnosis of BO was based on the presence of respiratory symptoms and air-trapping on expiratory lung high-resolution computed tomography in all patients, associated with irreversible airflow obstruction in seven cases. The median follow-up was 12.8 months (range: 5-29 months). All patients improved clinically, and both forced expiratory volume in 1 (FEV(1)) and mean expiratory flow values increased significantly during follow-up (534+/-268 ml in absolute values and 36+/-27% compared to pretreatment values for FEV(1); P<0.02). These encouraging results provide new insights in the therapeutic approach of BO after SCT and require confirmation in a larger group of patients with a longer follow-up.
  Bone Marrow Transplantation 05/2007; 39(9):547-53. · 3.75 Impact Factor
• Article: Characterisation of dendritic cell subsets in lung cancer micro-environments.

  A Bergeron, F El-Hage, M Kambouchner, D Lecossier, A Tazi
  [show abstract] [hide abstract]
  ABSTRACT: The aim of the current study was to seek evidence for a correlation between mediators present in lung cancer micro-environments and subsets of dendritic cells (DCs) infiltrating these tumours. Immunohistochemistry and recently available antibodies were used to define the phenotype of DCs present in surgical biopsies from 12 patients with lung carcinomas, and the local expression of chemokines potentially involved in the recruitment of these cells was evaluated, both at mRNA and protein levels. Real-time PCR was used to analyse the expression of mRNA coding for cytokines known to influence the maturation of DCs in vitro. Different subsets of myeloid DCs were present in lung cancers, but no plasmocytoid DCs were identified. Both Langerhans cells and CD1a+/Langerin cells were interspersed among tumour cells, in numbers that were correlated to the amounts of CC chemokine ligand 20 produced in these tumours. In most specimens, DC-specific intercellular adhesion molecule-grabbing nonintegrin-positive DCs were also present at the periphery of the tumour beds. No DC-lysosomal associated membrane protein-positive DCs were identified and CD83+ DCs were rarely present in the tumour stroma. All tumours expressed interleukin (IL)-10, transforming growth factor-beta and vascular endothelial growth factor, whereas IL-12 was virtually absent. Thus, various types of dendritic cells infiltrate lung carcinomas and display an immature phenotype, presumably because of the inhibitory cytokine micro-environment.
  European Respiratory Journal 01/2007; 28(6):1170-7. · 5.89 Impact Factor
• Article: [Evidence based pneumology: 3rd update workshop to the SPLF. Idiopathic diffuse interstitial pneumopathies].

  A Bergeron, A Tazi, B Crestani
  Revue des Maladies Respiratoires 01/2005; 21(6 Pt 1):1183-6. · 0.59 Impact Factor
• Article: A new clinical score for disease activity in Langerhans cell histiocytosis.

  Jean Donadieu, C Piguet, F Bernard, M Barkaoui, M Ouache, Y Bertrand, H Ibrahim, J F Emile, O Hermine, A Tazi, T Genereau, C Thomas
  [show abstract] [hide abstract]
  ABSTRACT: To develop an objective tool for assessing disease activity in patients with Langerhans cell histiocytosis (LCH). Scoring system was developed and applied to a database containing information on 612 patients. At diagnosis, the score distribution was highly asymmetrical: the score was between 0 and 2 in 74% of cases, 3-6 in 16%, 7-10 in 3%, and more than 10 in 6%. The 5-year mortality rates were 1, 4.4, and 43.4%, respectively, among patients with initial scores of 0-2, 3-6, and >6. Stability or an increase of the score at 6 weeks was highly predictive of death among patients with initial scores above 6, while score stability had no significant impact on vital outcome among patients with low or moderate scores at diagnosis. This LCH disease activity score provides an objective tool for assessing disease severity, both at diagnosis and during follow-up and treatment.
  Pediatric Blood & Cancer 12/2004; 43(7):770-6. · 1.89 Impact Factor
• Article: Expression of apoptosis-regulatory proteins in lesions of pulmonary Langerhans cell histiocytosis.

  J Marchal, M Kambouchner, A Tazi, D Valeyre, P Soler
  [show abstract] [hide abstract]
  ABSTRACT: Pulmonary Langerhans cell histiocytosis (PLCH) is characterized by the presence of lesions containing numerous activated Langerhans cells (LCs). An uncontrolled immune response sustained by activated LCs seems to be involved in the pathogenesis of the disease. The aim of this study was to establish whether disruption of LC apoptosis related to the expression of the Bcl-2 family proteins is implicated in the maintenance of PLCH lesions. Six patients with PLCH were evaluated by morphological and immunohistochemical techniques to explore the incidence of apoptosis in pathological LCs and to characterize the expression of Bcl-2-related proteins by these cells. Very few LCs present in PLCH lesions exhibited nuclear apoptotic changes or expressed cleaved caspase-3, whereas they all strongly expressed the anti-apoptotic molecule Bcl-x(L). Interestingly, pulmonary LCs present in intervening lung tissue not involved by the pathological process and known to be immature dendritic cells did not express Bcl-2 family proteins. These findings suggest that activated LCs present within PLCH lesions are poorly susceptible to apoptosis and, thus, are able to sustain the pathological process by causing continuous local stimulation of T cells. Functional studies are needed, however, to demonstrate that they are actually resistant to programmed cell death.
  Histopathology 08/2004; 45(1):20-8. · 3.08 Impact Factor
• Article: Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10.

  A Bergeron, P Soler, M Kambouchner, P Loiseau, B Milleron, D Valeyre, A J Hance, A Tazi
  [show abstract] [hide abstract]
  ABSTRACT: Modulation of cytokine expression represents a potentially useful approach for the treatment of idiopathic pulmonary fibrosis (IPF). To identify potential targets for such intervention, semi-quantitative reverse transcriptase-polymerase chain reaction was used to compare the expression of messenger ribonucleic acids (mRNAs) coding for 17 cytokines in lung tissue obtained from patients with IPF at the time of diagnosis and control subjects. Some cytokines were also studied at the protein level by immunohistochemical techniques. mRNAs coding for all of the cytokines evaluated were detected in both control and fibrotic lung samples. Only transforming growth factor (TGF)-beta and interleukin (IL)-10 mRNAs were quantitatively increased in lung biopsies from patients with IPF compared with those of controls, results confirmed at the protein level by immunohistochemistry. Although mRNAs for platelet-derived growth factor (PDGF)-BB and keratinocyte growth factor (KGF) were expressed in similar amounts in lungs from patients with IPF and controls, localised accumulation of both factors was also observed in IPF. Hyperplastic alveolar epithelial cells were a prominent source of cytokines, where IL-10, PDGF-BB and KGF were present in increased amounts, although increased accumulation in fibroblasts, smooth-muscle cells and matrix components was also observed (PDGF-BB, TGF-beta). These results offer new insights into the cytokines produced in the lung in idiopathic pulmonary fibrosis and suggest that modulation of the production of transforming growth factor-beta and interleukin-10 may represent a potentially useful therapeutic strategy for this disabling disease.
  European Respiratory Journal 08/2003; 22(1):69-76. · 5.89 Impact Factor
• Article: Hypersensitivity pneumonitis related to imatinib mesylate.

  A Bergeron, E Bergot, G Vilela, L Ades, A Devergie, H Espérou, G Socié, F Calvo, E Gluckman, P Ribaud, Ph Rousselot, A Tazi
  Journal of Clinical Oncology 11/2002; 20(20):4271-2. · 18.37 Impact Factor
• Article: Computed tomography of pulmonary sarcoid-like granulomas induced by complete Freund's adjuvant in rats.

  A Bergeron, J P Laissy, P Loiseau, E Schouman-Claeys, A J Hance, A Tazi
  [show abstract] [hide abstract]
  ABSTRACT: Intravenous injection of complete Freund's adjuvant (CFA) in rats has been proposed as an experimental model for pulmonary sarcoidosis, but only some animals develop granulomas. Because the detection of the presence of granulomas and evaluation of the extent of the reaction has required histological evaluation, this model has been of limited use in following the evolution of the granulomatous process. The present study evaluated the ability of lung computed tomography (CT) scanning to identify in vivo pulmonary granulomas induced by CFA in rats. Wistar rats were injected with CFA to induce pulmonary sarcoid-like granulomas, and the presence and extent of pulmonary abnormalities, as detected by spiral CT and histopathological analysis, were compared. Spiral CT had a high sensitivity and specificity for the detection of sarcoid-like granulomas in rats injected with CFA. The extent of the pulmonary granulomatous reaction as assessed by the two techniques strongly correlated (r=0.93, p<0.01). In contrast, the mean density of lungs containing granulomas was not significantly different from that of lungs with no granulomatous reaction. Thus, lung computed tomography appears to be a valuable tool for the in vivo evaluation of the pulmonary granulomatous reaction induced by complete Freund's adjuvant in rats. With the help of computed tomography, this experimental model should be suitable for the sequential study of pulmonary sarcoid-like granulomas, particularly in response to various therapeutic strategies.
  European Respiratory Journal 08/2001; 18(2):357-61. · 5.89 Impact Factor
• Article: 111In-pentetreotide scintigraphy in patients with Langerhans' cell histiocytosis.

  P Weinmann, B Crestani, A Tazi, T Genereau, H Mal, M Aubier, D Valeyre, J L Moretti, D Le Guludec, R Lebtahi
  [show abstract] [hide abstract]
  ABSTRACT: Langerhans' cell histiocytosis is a granulomatous disease that may involve multiple organs and the prognosis of which is highly variable. Because the prognosis depends particularly on the number of tissues involved, the accurate identification of the organs involved by granulomatous lesions is of critical importance. We hypothesized that 111In-pentetreotide scintigraphy would be useful for evaluation of patients with Langerhans' cells histiocytosis. Thirteen patients (38.3+/-10.4 y) with Langerhans' cell histiocytosis (8 patients with unifocal lung disease, 5 with multifocal disease) received intravenous 111In-pentetreotide (111-222 MBq), and planar images were obtained at 24 h after injection. Pulmonary uptake was quantified using a lung-to-background ratio (L/B) and compared with a population of 10 normal scintigrams. For the other sites, uptake of radioactivity in disease-related areas was visually assessed. Ten of 12 patients with lung involvement had increased lung uptake (UB, 2.23+/-0.49 versus 1.34+/-0.07; P < 0.001). In the patients with multifocal disease, increased 111In-pentetreotide uptake was found in disease-related areas such as the salivary glands, the skin, the soft tissues, and the bones. However, somatostatin receptor imaging was insensitive for detecting central nervous system and liver involvement and most skin lesions. 111In-pentetreotide imaging may be useful in Langerhans' cell histiocytosis. Further study will indicate whether 111In-pentetreotide is a relevant tracer in the management of histiocytosis.
  Journal of Nuclear Medicine 11/2000; 41(11):1808-12. · 6.38 Impact Factor
• Article: Is high-resolution computed tomography a reliable tool to predict the histopathological activity of pulmonary Langerhans cell histiocytosis?

  P Soler, A Bergeron, M Kambouchner, O Groussard, M Brauner, P Grenier, B Crestani, H Mal, A Tazi, J P Battesti, P Loiseau, D Valeyre
  [show abstract] [hide abstract]
  ABSTRACT: High-resolution computed tomography (HRCT) has proved to be very useful in the diagnosis and follow-up of pulmonary Langerhans cell histiocytosis (PLCH), but the precise relationships between nodules and thin-wall cysts observed by HRCT, and granulomatous or cystic lesions present in lung tissue, remain to be established. The aim of this study was to compare quantitative data obtained by HRCT and those obtained by histopathological examination of corresponding lung tissue specimens in patients with biopsy-proven PLCH. The results demonstrated that the extent of nodular abnormalities was strongly correlated with the density of florid granulomatous lesions in lung tissue. A strong correlation was also found between the extent of cystic abnormalities and the density of cavitary lesions, but the latter included both still inflammatory cavitary granulomas and cicatricial fibrous cysts. Interestingly, small isolated florid granulomas were found in lung tissue from most patients with a predominant cystic CT scan pattern. Taken together, these results demonstrate that HRCT has to be considered with caution to evaluate the histopathological activity of PLCH. Patients presenting with predominant HRCT cystic abnormalities should benefit from a long-term follow-up. Because these patients are susceptible to developing severe respiratory insufficiency, they should also be considered for treatment as soon as an effective therapy for LCH is available.
  American Journal of Respiratory and Critical Care Medicine 08/2000; 162(1):264-70. · 11.08 Impact Factor
• Article: Adult pulmonary Langerhans' cell histiocytosis.

  A Tazi, P Soler, A J Hance
  Thorax 06/2000; 55(5):405-16. · 6.84 Impact Factor
• Article: [T lymphocytes in sarcoidosis].

  A Tazi, A J Hance
  [show abstract] [hide abstract]
  ABSTRACT: IMPORTANCE OF T-LYMPHOCYTES IN SARCOIDOSIS: Sarcoidosis is thought to result from an uncontrolled granulomatous immune response. T-lymphocytes are an essential component of this immune reaction. The recognition of specific antigens through receptors expressed on the cell membrane activates the T-cells, resulting in the expression of effector functions that ultimately control granuloma formation. T-cells participating in sarcoid reactions are readily accessible using bronchoalveolar lavage, and have been intensively studied. SPECIFICITY OF T-CELLS: Several groups have evaluated the diversity of T-cell receptors expressed by T-cells from patients with sarcoidosis. These studies have demonstrated that oligoclonal T-cell populations are present both in the lung and blood of these patients, findings that support the conclusion that antigen-induced immune responses play a role in the pathogenesis of sarcoidosis. The identification of the antigen(s) recognized by these cells remains an important goal, and may help identify etiologic agents. CYTOKINE PRODUCTION: Considerable progress has been made in characterizing the cytokines produced by T-lymphocytes and other cells participating in the granulomatous reaction. The modulation of the activity of these mediators represents a promising approach for the development of more specific therapeutic agents.
  La Presse Médicale 11/1999; 28(31):1723-8. · 0.67 Impact Factor
• Source

  Available from: ersjournals.com

  Article: Familial extensive idiopathic bilateral pleural fibrosis.

  E Azoulay, B Paugam, M F Heymann, M Kambouchner, A Haloun, D Valeyre, J P Battesti, A Tazi
  [show abstract] [hide abstract]
  ABSTRACT: The authors report three sisters with bilateral isolated apical pleural fibrosis of unknown origin, which did not respond to empirical antituberculosis therapy and oral corticosteroids. The disease evolved in an unrelenting fashion producing pleural fibrosis at the lung bases and leading to the death of two sisters and to lung transplantation in the other one. There was no history of other familial disease or consanguinity. The particular features of these cases and the differences from other reports of apparently cryptogenic pleural fibrosis are outlined.
  European Respiratory Journal 11/1999; 14(4):971-3. · 5.89 Impact Factor